Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Fazamorexant (YZJ-1139) in Healthy Participants
NCT06673927Phase 1Completed
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fazamorexant in Insomnia (2 arms), sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Primary endpoint: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Dec 2017; status: completed.
02
Drugs
fazamorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06673927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673927.